Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Necchi

Showing results (11-20 of 495) with videos related to

Pageof 50
Sort By:
BJU International|August 18, 2020
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancerFrancesco Montorsi, Marco Moschini, Andrea Necchi
Lancet (London, England)|October 20, 2025
Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancerAndrea Necchi, Alberto Briganti, Francesco Montorsi
European Urology|May 5, 2020
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65Francesco Montorsi, Marco Bandini, Andrea Necchi
Urologic Oncology|September 20, 2020
Second line salvage systemic therapy for advanced penile cancerJad Chahoud, Monica Tamil, Andrea Necchi
European Urology|June 30, 2026
Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024Antonio Cigliola, Andrea Necchi, Umberto Capitanio
European Urology|October 16, 2018
Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO)Andrea Necchi, Antonella Messina, Alberto Briganti
Translational Andrology and Urology|January 23, 2018
Current markers and their value in the era of immuno-oncologyFriedrich-Carl von Rundstedt, Andrea Necchi
European Urology Focus|April 7, 2021
Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9Francesco Montorsi, Marco Bandini, Andrea Necchi
European Urology|April 15, 2018
Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?Guru Sonpavde, George Dranitsaris, Andrea Necchi
Future Oncology (London, England)|June 22, 2018
Nivolumab and its use in the second-line treatment of metastatic urothelial cancerDaniele Raggi, Andrea Necchi, Patrizia Giannatempo
Pageof 50

Showing results (11-20 of 495) with videos related to

Sort By:
Pageof 50
BJU International|August 18, 2020
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancerFrancesco Montorsi, Marco Moschini, Andrea Necchi
Lancet (London, England)|October 20, 2025
Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancerAndrea Necchi, Alberto Briganti, Francesco Montorsi
European Urology|May 5, 2020
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65Francesco Montorsi, Marco Bandini, Andrea Necchi
Urologic Oncology|September 20, 2020
Second line salvage systemic therapy for advanced penile cancerJad Chahoud, Monica Tamil, Andrea Necchi
European Urology|June 30, 2026
Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024Antonio Cigliola, Andrea Necchi, Umberto Capitanio
European Urology|October 16, 2018
Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO)Andrea Necchi, Antonella Messina, Alberto Briganti
Translational Andrology and Urology|January 23, 2018
Current markers and their value in the era of immuno-oncologyFriedrich-Carl von Rundstedt, Andrea Necchi
European Urology Focus|April 7, 2021
Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9Francesco Montorsi, Marco Bandini, Andrea Necchi
European Urology|April 15, 2018
Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?Guru Sonpavde, George Dranitsaris, Andrea Necchi
Future Oncology (London, England)|June 22, 2018
Nivolumab and its use in the second-line treatment of metastatic urothelial cancerDaniele Raggi, Andrea Necchi, Patrizia Giannatempo
Pageof 50